Compare · AZN vs DYN
AZN vs DYN
Side-by-side comparison of AstraZeneca PLC (AZN) and Dyne Therapeutics Inc. (DYN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and DYN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $258.47B, about 90.5x DYN ($2.86B).
- Over the past year, AZN is up 95.4% and DYN is down 13.0% - AZN leads by 108.4 points.
- AZN has been more active in the news (18 items in the past 4 weeks vs 3 for DYN).
- AZN has more recent analyst coverage (25 ratings vs 23 for DYN).
- Company
- AstraZeneca PLC
- Dyne Therapeutics Inc.
- Price
- -
- -
- Market cap
- $258.47B
- $2.86B
- 1M return
- -0.43%
- -21.05%
- 1Y return
- +95.37%
- -13.03%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 18
- 3
- Recent ratings
- 25
- 23
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Latest AZN
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SEC Form 4 filed by AstraZeneca PLC
- AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- SEC Form 6-K filed by AstraZeneca PLC
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- SEC Form 6-K filed by AstraZeneca PLC
Latest DYN
- SEC Form 4 filed by Dyne Therapeutics Inc.
- Dyne Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dyne Therapeutics downgraded by Analyst with a new price target
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- Chief Commercial Officer Friedl-Naderer Johanna sold $25,408 worth of shares (1,085 units at $23.42) as part of a pre-agreed trading plan, decreasing direct ownership by 0.70% to 152,897 units (SEC Form 4) to cover taxes
- Chief Medical Officer Kerr Douglas sold $115,546 worth of shares (5,035 units at $22.95) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 162,564 units (SEC Form 4) (for withholding tax)
- CEO & President Cox John sold $106,823 worth of shares (5,658 units at $18.88) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 357,507 units (SEC Form 4) (tax withholding)